Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial
EndoPredict 检测在接受随机、双盲 III 期 UNIRAD 试验筛查的激素受体阳性、人表皮生长因子受体 2 阴性原发性乳腺癌患者中的预后价值
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.103443
Penault-Llorca, F; Dalenc, F; Chabaud, S; Cottu, P; Allouache, D; Cameron, D; Grenier, J; Venat Bouvet, L; Jegannathen, A; Campone, M; Debled, M; Hardy-Bessard, A-C; Giacchetti, S; Barthelemy, P; Kaluzinski, L; Mailliez, A; Mouret-Reynier, M-A; Legouffe, E; Cayre, A; Martinez, M; Delbaldo, C; Mollon-Grange, D; Macaskill, E J; Sephton, M; Stefani, L; Belgadi, B; Winter, M; Orfeuvre, H; Lacroix-Triki, M; Bonnefoi, H; Bliss, J; Canon, J-L; Lemonnier, J; Andre, F; Bachelot, T
